Vaxelis

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification[1] issued on	Commission Decision Issued[2] / amended on	Product Information affected[3]	Summary
IA/0145	B.II.e.1.b.3 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Deletion of an immediate packaging container without a complete deletion of a strength or pharmaceutical form	17/07/2024		SmPC, Labelling and PL	

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

II/0141	B.I.e.2 - Introduction of a post approval change management protocol related to the AS	06/06/2024	n/a		
IB/0143/G	This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	08/05/2024	n/a		
IB/0142	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	08/05/2024	n/a		
IB/0139/G	This was an application for a group of variations. B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting	15/04/2024	n/a		

	material/intermediate/reagent - Tightening of specification limits B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.z - Change in control of the AS - Other variation B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State				
II/0136/G	This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a	11/01/2024	n/a		

	biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate				
IB/0138	B.II.d.2.z - Change in test procedure for the finished product - Other variation	04/01/2024	n/a		
II/0134	Update of section 4.8 of the SmPC in order to add Extensive swelling of vaccinated limb to the list of adverse drug reactions (ADRs) with frequency rare and to update its description based on the cumulative review of clinical studies, literature and safety database. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	14/12/2023		SmPC and PL	The Vaxelis SmPC section 4.8 has been updated to include Extensive swelling of vaccinated limb with frequency rare. For more information, please refer to the Summary of Product Characteristics.
II/0128	Update of section 4.5 in order to add drug-drug interaction information with meningococcal B conjugate vaccine based on final results from study	07/12/2023		SmPC and PL	The Vaxelis SmPC section 4.5 has been updated to include information on drug-drug interaction information with meningococcal B conjugate. Vaxelis may be administered at

	OVG 2018/05 - Immunogenicity and reactogenicity of concomitantly administered hexavalent and group B meningococcal vaccines in infancy; this is an open-label, non-inferiority, randomized clinical trial that compared the immune response and assessed the safety of Vaxelis and control vaccine (Infanrix hexa) when co-administered with 4 component meningococcal B vaccine (4CMenB) along with other routine infant vaccines. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				the same time with meningococcal B vaccines. Due to an increase in some adverse reactions when a different hexavalent vaccine with a similar reactogenicity profile to Vaxelis was co-administered with Meningococcal B vaccine, separate vaccinations can be considered. For more information, please refer to the Summary of Product Characteristics.
II/0126	Update of sections 4.2 and 5.1 of the SmPC in order to add information on interchangeable use of Vaxelis with other hexavalent vaccines based on final results from Study V419-016. In addition, the MAH took this opportunity to introduce minor editorial changes. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	30/11/2023		SmPC	The Vaxelis SmPC sections 4.2 and 5.1 have been updated to include information on interchangeable use of Vaxelis with other hexavalent vaccines. Vaxelis may be used as a booster dose in children who received another hexavalent vaccine for their primary series. For more information, please refer to the Summary of Product Characteristics.
II/0131	B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol	23/11/2023	n/a		

II/0132	B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol	09/11/2023	n/a		
IB/0133/G	This was an application for a group of variations. B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	25/10/2023	n/a		
IB/0135	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	24/10/2023	n/a		
PSUSA/10469 /202302	Periodic Safety Update EU Single assessment - diphtheria / tetanus / pertussis (acellular, component) / hepatitis B (rDNA) / poliomyelitis (inactivated) / haemophilus type b conjugate vaccine (adsorbed)	28/09/2023	n/a		PRAC Recommendation - maintenance

IB/0129	B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	26/07/2023	n/a		
IB/0130	B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits	25/07/2023	n/a		
IB/0125/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation	04/07/2023	n/a		
IA/0127	B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits	30/06/2023	n/a		
IB/0123	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	19/06/2023	n/a		
IB/0124	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	16/06/2023	n/a		
IB/0121	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other	16/06/2023	n/a		

	changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate				
II/0119/G	This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test	08/06/2023	n/a		
IA/0120	B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised	13/04/2023	n/a		
IB/0118/G	This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or	24/03/2023	n/a		

	starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate				
II/0115	B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol	23/03/2023	n/a		
IB/0117	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	14/02/2023	n/a		
IB/0116	B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation	13/02/2023	n/a		
II/0110	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	26/01/2023		SmPC and PL	"Hypersensitivity" and "Anaphylactic reaction" were added to the table of adverse events reported during post-marketing use in Section 4.8 of the SmPC, with 'rare' as frequency. Accordingly, "allergic reaction, serious allergic reaction (anaphylactic reaction)" was added to the list of side effects in section 4 of the PL with frequency 'rare'. Consequently, the paragraph on hypersensitivity and anaphylactic reaction - previously part of the description of selected adverse reactions reported with other vaccines containing the components or constituents of Vaxelis without regard to causality or frequency – was deleted from the SmPC (section 4.8) and the PL (section 4) approved with this variation.

					For more information, please refer to the Summary of Product Characteristics.
WS/2361	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	19/01/2023	n/a		
IB/0113	B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product	16/12/2022		SmPC	
IA/0114	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	13/12/2022	n/a		
II/0109	B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol	01/12/2022	n/a		
WS/2360	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other	01/12/2022	n/a		

	changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate				
II/0107	B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol	17/11/2022	n/a		
IB/0111/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	07/11/2022	n/a		

II/0104/G	This was an application for a group of variations. B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol	08/09/2022	09/12/2022	SmPC and PL	
IB/0105/G	This was an application for a group of variations. B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting	18/08/2022	n/a		

	material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits				
IA/0106	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	10/08/2022	09/12/2022	Annex II	
II/0097	B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range	21/07/2022	n/a		
IB/0102/G	This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	25/05/2022	n/a		

	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)				
IB/0101	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	17/05/2022	n/a		
IB/0100	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	17/05/2022	n/a		
IB/0098	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	13/04/2022	n/a		
N/0099	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	04/04/2022	09/12/2022	PL	
II/0095	B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS	17/03/2022	n/a		

II/0093/G	This was an application for a group of variations. B.I.c.1.b - Change in immediate packaging of the AS - Qualitative and/or quantitative composition for sterile and non-frozen biological/immunological ASs B.I.b.z - Change in control of the AS - Other variation B.I.b.z - Change in control of the AS - Other variation B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol	10/02/2022	n/a		
IA/0096/G	This was an application for a group of variations.	07/02/2022	n/a		

	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure				
II/0088	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	27/01/2022	09/12/2022	SmPC, Labelling and PL	
WS/2173	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation	13/01/2022	n/a		
IB/0094/G	This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting	22/12/2021	n/a		

	material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation				
IB/0092/G	This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	13/12/2021	n/a		
II/0090	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	02/12/2021	09/12/2022	SmPC and PL	
WS/2143	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation	11/11/2021	n/a		
II/0085/G	This was an application for a group of variations. B.I.a.2.c - Changes in the manufacturing process of	16/09/2021	n/a		

	the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR				
IB/0087	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	26/08/2021	n/a		
IA/0086	B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer	02/08/2021	n/a		

IB/0084	B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation	13/07/2021	n/a		
II/0079	B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol	17/06/2021	n/a		
IB/0082	B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	14/06/2021	n/a		
IA/0083	B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer	03/06/2021	n/a		
II/0077	B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation	28/05/2021	n/a		
II/0076/G	This was an application for a group of variations. B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol B.II.d.2.c - Change in test procedure for the finished	20/05/2021	n/a		

	product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol				
IA/0081/G	This was an application for a group of variations. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	06/05/2021	n/a		
IB/0080	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	06/05/2021	n/a		
IB/0078/G	This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material	05/05/2021	n/a		

	B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-				

	significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation				
II/0075	B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol	15/04/2021	n/a		
II/0073	B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol	18/03/2021	n/a		
II/0074	B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol	11/03/2021	n/a		
II/0070	B.II.d.1.f - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product	04/02/2021	n/a		
IB/0072	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting	18/12/2020	n/a		

	material/intermediate/reagent - Other variation				
IB/0071/G	This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	16/12/2020	n/a		
IB/0068	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	10/11/2020	n/a		
IB/0069	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	06/11/2020	n/a		
IB/0067/G	This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.z - Quality change - Active substance - Other variation	22/10/2020	n/a		
PSUSA/10469 /202002	Periodic Safety Update EU Single assessment - diphtheria / tetanus / pertussis (acellular, component) / hepatitis B (rDNA) / poliomyelitis (inactivated) / haemophilus type b conjugate vaccine	01/10/2020	n/a		PRAC Recommendation - maintenance

	(adsorbed)				
R/0065	Renewal of the marketing authorisation.	23/07/2020	24/09/2020	SmPC, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Vaxelis in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.
WS/1804/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol	30/04/2020	n/a		
IB/0064/G	This was an application for a group of variations. B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting	29/04/2020	n/a		

	material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material) B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)				
IB/0057/G	This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	08/04/2020	n/a		

	B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer				
IB/0062	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	06/04/2020	n/a		
IB/0061	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	06/04/2020	n/a		
II/0055	B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol	02/04/2020	n/a		
IA/0063/G	This was an application for a group of variations. B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	27/03/2020	n/a		

IA/0060	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	27/03/2020	n/a		
IB/0059	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	24/03/2020	n/a		
IB/0056	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	28/02/2020	n/a		
II/0054	Update of section 4.8 of the Vaxelis SmPC in order to add Hypotonic Hyporesponsive Episode to the list of post-marketing adverse events, based on a cumulative assessment of post-marketing data from the Marketing authorisation holder (MAH) global safety database. The Package Leaflet is updated accordingly. In addition, the MAH made minor editorial changes to the product information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	13/02/2020	24/09/2020	SmPC and PL	Hypotonic Hyporesponsive Episode is added as an adverse reaction with unknown frequency. Because these events of were reported from a population of uncertain size, it is generally not possible to reliably estimate their frequency or to establish, a causal relationship to the vaccine. The PL have been updated accordingly.
II/0052/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new	23/01/2020	24/09/2020	SmPC, Labelling and PL	

	container - Sterile medicinal products and biological/immunological medicinal products B.II.e.1.z - Change in immediate packaging of the finished product - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing				
IB/0053	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	09/12/2019	n/a		
IB/0051	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	10/10/2019	n/a		
PSUSA/10469 /201902	Periodic Safety Update EU Single assessment - diphtheria / tetanus / pertussis (acellular, component) / hepatitis B (rDNA) / poliomyelitis (inactivated) / haemophilus type b conjugate vaccine (adsorbed)	05/09/2019	n/a		PRAC Recommendation - maintenance
IA/0050/G	This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits	26/07/2019	n/a		

	B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)				
IB/0049	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	05/06/2019	n/a		
IA/0047	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	03/04/2019	n/a		
PSUSA/10469 /201808	Periodic Safety Update EU Single assessment - diphtheria / tetanus / pertussis (acellular, component) / hepatitis B (rDNA) / poliomyelitis (inactivated) / haemophilus type b conjugate vaccine (adsorbed)	14/03/2019	n/a		PRAC Recommendation - maintenance
IA/0046	B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method	23/01/2019	n/a		
IB/0045	B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product	14/01/2019	13/01/2020	SmPC and PL	

IAIN/0044/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	12/12/2018	n/a		
IA/0043	B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised	12/12/2018	n/a		
II/0040	B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS	08/11/2018	n/a		
IB/0041	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	10/10/2018	n/a		
IB/0039/G	This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	06/09/2018	n/a		

	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data				
PSUSA/10469 /201802	Periodic Safety Update EU Single assessment - diphtheria / tetanus / pertussis (acellular, component) / hepatitis B (rDNA) / poliomyelitis (inactivated) / haemophilus type b conjugate vaccine (adsorbed)	06/09/2018	n/a		PRAC Recommendation - maintenance
IB/0038	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	05/09/2018	n/a		
IB/0037	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	26/06/2018	n/a		
IB/0036/G	This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	26/06/2018	n/a		
II/0030	B.I.z - Quality change - Active substance - Other variation	31/05/2018	n/a		

IB/0034	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	16/05/2018	n/a		
IB/0033	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	16/05/2018	n/a		
IB/0032/G	This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	16/05/2018	n/a		
IA/0031/G	This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters	02/05/2018	n/a		

	and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)				
N/0029	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	06/04/2018	13/01/2020	PL	
II/0026	B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol	15/03/2018	n/a		
PSUSA/10469 /201708	Periodic Safety Update EU Single assessment - diphtheria / tetanus / pertussis (acellular, component) / hepatitis B (rDNA) / poliomyelitis (inactivated) / haemophilus type b conjugate vaccine (adsorbed)	08/03/2018	n/a		PRAC Recommendation - maintenance
IB/0028/G	This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	26/02/2018	n/a		

	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation				
IB/0025/G	This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	22/01/2018	n/a		
IB/0023	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	11/01/2018	n/a		
II/0021	Update of section 5.1 of the SmPC in order to update the efficacy section on immune persistence based on the final results from study PRI03C - Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4- to 5-year-old Children Previously Vaccinated with a 2 dose or 3 dose Infants Series and Toddler dose of Vaxelis or INFANRIX hexa listed as P46 study in the PIP. The RMP version 2.2 has also been submitted.	11/01/2018	15/03/2018	SmPC and Labelling	The SmPC section 5.1 has been updated following the completion of PRI03C study with the data on long- term immune persistence following the vaccination with Vaxelis. The purpose of this study was to provide the results of the long-term persistence of anti-Hepatitis B surface antigen (antiHBsAg) and pertussis antibody (PT, FHA, PRN and FIM) responses in children previously vaccinated with Vaxelis or Infanrix hexa. The data was collected 3 to 4 years after completion of a 2+1 or 3+1 vaccination schedule.

	In addition, the MAH took the opportunity to introduce editorial changes in Annex IIIA. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				The proportion of children seroprotected (anti-HBsAg ≥10 mIU/mL – accepted correlate of protection) after those vaccination schedules decreased by approximately 30% in approximately 4 years. Considerable study data suggest that individuals who have ever had a seroprotective response to HB vaccination will have a memory response that is protective against clinical disease if exposed to the HB virus. The immunogenicity findings also support the long-term persistence of pertussis antibody responses. After approximately 4 years, the percentages of children with anti-pertussis antibodies above Lower Limit of Quantification (LLOQ) were as follows: anti-PT 58.4%, anti-FHA 80.9%, anti-PRN 66.1% and anti-FIM 94.3%. Clinical data had confirmed that Vaxelis is comparable to currently licensed vaccine controls with respect to immunogenicity and safety, when given concomitantly with other licensed routine paediatric vaccines.
IB/0027	B.II.d.2.z - Change in test procedure for the finished product - Other variation	20/12/2017	n/a		
IB/0024	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	06/12/2017	n/a		
PSUSA/10469 /201702	Periodic Safety Update EU Single assessment - diphtheria / tetanus / pertussis (acellular, component) / hepatitis B (rDNA) / poliomyelitis (inactivated) / haemophilus type b conjugate vaccine (adsorbed)	28/09/2017	n/a		PRAC Recommendation - maintenance

IA/0020	B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method	22/09/2017	n/a		
IB/0019	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	15/08/2017	n/a		
IB/0017/G	This was an application for a group of variations. B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation	10/08/2017	n/a		
IB/0018	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	09/08/2017	n/a		
IB/0015	B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)	21/07/2017	n/a		
II/0012/G	This was an application for a group of variations. B.I.a.2.c - Changes in the manufacturing process of	20/07/2017	n/a		

	the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation				

	B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material				
N/0016	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	04/07/2017	15/03/2018	Labelling and PL	
IB/0013/G	This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.III.1.z - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Other variation B.III.1.z - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Other variation	09/06/2017	n/a		
IB/0011	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	08/06/2017	n/a		
IB/0010	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	26/04/2017	n/a		

IB/0009	B.I.z - Quality change - Active substance - Other variation	06/04/2017	n/a		
IAIN/0008	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	16/03/2017	15/03/2018	Annex II and PL	
PSUSA/10469 /201608	Periodic Safety Update EU Single assessment - diphtheria / tetanus / pertussis (acellular, component) / hepatitis B (rDNA) / poliomyelitis (inactivated) / haemophilus type b conjugate vaccine (adsorbed)	09/03/2017	n/a		PRAC Recommendation - maintenance
T/0007	Transfer of Marketing Authorisation from Sanofi Pasteur MSD SNC to MCM Vaccine B.V. Transfer of Marketing Authorisation	19/12/2016	27/01/2017	SmPC, Labelling and PL	
IB/0005	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	24/10/2016	n/a		
IA/0004/G	This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)	19/10/2016	n/a		

	B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)				
IA/0003	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	19/10/2016	n/a		
II/0002	B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product	15/09/2016	n/a		
IAIN/0001/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	25/05/2016	27/01/2017	Annex II and PL	